A cluster-randomised, parallel group, controlled intervention study of genetic prostate cancer risk assessment and use of psa tests in general practice-the ProCaRis study: Study protocol

BMJ Open

Volumn 3, Issue 3, 2013, Pages

  Kirkegaard, Pia ^a   Vedsted, Peter ^a   Edwards, Adrian ^b   Fenger Grøn, Morten ^a   Bro, Flemming ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; CLINICAL PRACTICE; CONTROLLED STUDY; CULTURAL ANTHROPOLOGY; GENETIC RISK; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SOCIAL ASPECT;

EID: 84876136990     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-002452     Document Type: Article

References (64)

1. Damber J, Aus G. Prostate cancer. Lancet 2008;371:1710-21. (Pubitemid 351671887)
2. Hoffman RM. Screening for prostate cancer. N Engl J Med 2011;365:2013-19.
3. Kim J, Davis JW. Prostate cancer screening-time to abandon one-size-fits-all approach? JAMA 2011;306:2717-18.
4. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
5. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-90.
6. Smith DP, King MT, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer: Population based cohort study. BMJ 2009;339:b4817.
7. Ilic D, O'Connor D, Green S, et al. Screening for prostate cancer: An updated Cochrane systematic review. BJU Int 2011;107:882-91.
8. Hansen BL, Lose G, McNair SB, et al. [DSAM: Klinisk vejledning for almen medicin. Udredning og behandling af nedre urinvejssymptomer hos mænd og kvinder]. 1st edition. Viby J, Scanprint, eds. Dansk Selskab for Almen Medicin og Fonden for Tidsskrift for Praktisk Lægegerning. 2009 .
9. Mukai TO, Bro F, Pedersen KV, et al. Use of prostate-specific antigen testing. Ugeskr Laeger 2010;172:696-700.
10. Aly M, Wiklund F, Xu J, et al. Polygenic risk score improves prostate cancer risk prediction: Results from the Stockholm-1 cohort study. Eur Urol 2011;60:21-8.
11. Vickers AJ, Cronin AM, Roobol MJ, et al. The relationship between prostate-specific antigen and prostate cancer risk: The Prostate Biopsy Collaborative Group. Clin Cancer Res 2010;16:4374-81.
12. Jin G, Lu L, Cooney KA, et al. Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: Evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 2012;131:1095-103.
13. Zhu X, Albertsen PC, Andriole GL, et al. Risk-based prostate cancer screening. Eur Urol 2012;61:652-61.
14. Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79-85.
15. Doukas DJ, Li Y. Men's values-based factors on prostate cancer risk genetic testing: A telephone survey. BMC Med Genet 2004;5:28.
16. Bratt O, Kristoffersson U, Lundgren R, et al. Sons of men with prostate cancer: Their attitudes regarding possible inheritance of prostate cancer, screening, and genetic testing. Urology 1997;50:360-5. (Pubitemid 27428112)
17. Bratt O, Damber JE, Emanuelsson M, et al. Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. Eur J Cancer 2000;36:235-41. (Pubitemid 30102201)
18. James KM, Cowl CT, Tilburt JC, et al. Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic. Mayo Clin Proc 2011;86:933-40.
19. Jacobsen PB, Lamonde LA, Honour M, et al. Relation of family history of prostate cancer to perceived vulnerability and screening behavior. Psychooncology 2004;13:80-5. (Pubitemid 38247764)
20. Bratt O, Emanuelsson M, Gronberg H. Psychological aspects of screening in families with hereditary prostate cancer. Scand J Urol Nephrol 2003;37:5-9. (Pubitemid 36246204)
21. Bratt O, Damber JE, Emanuelsson M, et al. Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. Eur J Cancer 2000; 36:235-41. (Pubitemid 30102201)
22. Spain P, Carpenter WR, Talcott JA, et al. Perceived family history risk and symptomatic diagnosis of prostate cancer: The North Carolina Prostate Cancer Outcomes study. Cancer 2008;113:2180-7.
23. Julian-Reynier C, Mancini J, Mouret-Fourme E, et al. Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations. Eur J Hum Genet 2011;19:500-6.
24. Leblond D, Bredart A, Dolbeault S, et al. Cognitive, emotional and behavioral impact of an uncertain outcome after study of BRCA1/2: Review of the literature. Bull Cancer 2011;98:184-98.
25. Quillin JM, Bodurtha JN, McClish D, et al. Genetic risk, perceived risk, and cancer worry in daughters of breast cancer patients. J Genet Couns 2011;20:157-64.
26. Menko FH, Jansen AM, Stoel RD, et al. Perceiving cancer-risks and heredity-likelihood in genetic-counseling: How counselees recall and interpret BRCA 1/2-test results. Clin Genet 2011;79:207-18.
27. Henneman L, Timmermans DR, Bouwman CM, et al. 'A low risk is still a risk': Exploring women's attitudes towards genetic testing for breast cancer susceptibility in order to target disease prevention. Public Health Genomics 2011;14:238-47.
28. Hallowell N, Foster C, Eeles R, et al. Accommodating risk: Responses to BRCA1/2 genetic testing of women who have had cancer. Soc Sci Med 2004;59:553-65. (Pubitemid 38622299)
29. Graves KD, Gatammah R, Peshkin BN, et al. BRCA1/2 genetic testing uptake and psychosocial outcomes in men. Fam Cancer 2011;10:213-23.
30. Schiffman SC, Chagpar AB. Does a family history of male breast cancer influence risk perception and use of genetic testing? Am Surg 2010;76:879-82.
31. Hallowell N, Ardern-Jones A, Eeles R, et al. Communication about genetic testing in families of male BRCA1/2 carriers and non-carriers: Patterns, priorities and problems. Clin Genet 2005;67:492-502. (Pubitemid 40637447)
32. Hallowell N, Ardern-Jones A, Eeles R, et al. Men's decision-making about predictive BRCA1/2 testing: The role of family. J Genet Couns 2005;14:207-17. (Pubitemid 40909689)
33. White A, Richardson N. Gendered epidemiology: Making men's health visible in epidemiological research. Public Health 2011;125:407-10.
34. White AK, Thomson CS, Forman D, et al. Men's health and the excess burden of cancer in men. Eur Urol Suppl 2010;9:467-70.
35. Bates LM, Hankivsky O, Springer KW. Gender and health inequities: A comment on the final report of the WHO commission on the social determinants of health. Soc Sci Med 2009;69:1002-4.
36. Byrnes JP, Miller DC, Schafer WD. Gender differences in risk taking: A meta-analysis. Psychol Bull 1999;125:367-83.
37. Schubert R. Analyzing and managing risks-on the importance of gender differences in risk attitudes. Manage Finance 2006;32:706.
38. Gustafson PE. Gender differences in risk perception: Theoretical and methodological perspectives. Risk Anal 1998;18:805.
39. Pedersen KM, Andersen JS, Sondergaard J. General practice and primary health care in Denmark. J Am Board Fam Med 2012;25 (Suppl 1):S34-8.
40. Edwards A, Elwyn G, Hood K, et al. The development of COMRADE-a patient-based outcome measure to evaluate the effectiveness of risk communication and treatment decision making in consultations. Patient Educ Couns 2003;50:311-22. (Pubitemid 36945306)
41. Hilden PK, Middelthon AL. Qualitative methods in medical research-an ethnographic perspective. Tidsskr nor Laegeforen 2002;122:2473-6. (Pubitemid 35291334)
42. Hammersley M, Atkinson P. Ethnography. Principles in practice. London: Routledge, 2002.
43. Reeves S, Kuper A, Hodges BD. Qualitative research methodologies: Ethnography. BMJ 2008;337:a1020.
44. Seale C, Charteris-Black J, Dumelow C, et al. The effect of joint interviewing on the performance of gender. Field Methods 2008;20:1-22.
45. Schulz KF, Altman DG, Moher D. For the CONSORT Group. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
46. Tulloch J, Lupton D. Risk and everyday life. London: SAGE Publications, 2003.
47. Lupton D. Risk. London: Routledge, 1999.
48. Douglas M. Risk and blame: Essays in cultural theory. London: Routledge, 1994.
49. Kavanagh AM, Broom DH. Embodied risk: My body, myself? Soc Sci Med 1998;46:437-44. (Pubitemid 28022407)
50. Novas C, Rose N. Genetic risk and the birth of the somatic individual. Econ Soc 2000;29:485-513.
51. Lock M. Part 3: The human in the body demoting the genetic body. Anthropologica 2009;51:159-72.
52. Lock M, Freeman J, Chilibeck G, et al. Susceptibility genes and the question of embodied identity. Med Anthropol Q 2007;21:256-76.
53. Chilibeck G, Lock M, Sehdev M. Postgenomics, uncertain futures, and the familiarization of susceptibility genes. Soc Sci Med 2011;72:1768-75.
54. Han PK, Klein WM, Lehman TC, et al. Laypersons' responses to the communication of uncertainty regarding cancer risk estimates. Med Decis Making 2009;29:391-403.
55. Lee SJ. Uncertain futures: Individual risk and social context in decision-making in cancer screening. Health Risk Soc 2010;12:101-17.
56. Boholm Å. The cultural nature of risk: Can there be an anthropology of uncertainty? Ethnos 2003;68:159.
57. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012;367:1998-2005.
58. Woloshin S, Schwartz LM, Black WC, et al. Cancer screening campaigns-getting past uninformative persuasion. N Engl J Med 2012;367:1677-9.
59. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-32.
60. Rantala J, Platten U, Lindgren G, et al. Risk perception after genetic counseling in patients with increased risk of cancer. Hered Cancer Clin Pract 2009;7:15.
61. Conrad P. The shifting engines of medicalization. J Health Soc Behav 2005;46:3-14. (Pubitemid 41503889)
62. Timmermans S, Haas S. Towards a sociology of disease. Sociol Health Illn 2008;30:659-76.
63. Lipworth WL, Davey HM, Carter SM, et al. Beliefs and beyond: What can we learn from qualitative studies of lay people's understandings of cancer risk? Health Expect 2010;13:113-24.
64. Petersen A, Lupton D. The new public health: Health and self in the age of risk. London: SAGE, 1996.